Daniel Wiśniewski, Izabela Uzar
The pharmacotherapy for rheumatoid arthritis. An overview of world data
Rheumatoid arthritis is one of the most common autoimmune diseases of the skeletal system. Pharmacotherapy has evolved from non‑specific anti‑inflammatory drugs to increasingly advanced biological agents. The latest activities involve the development of further biosimilar substitutes for known biological preparations. Despite the relatively good knowledge of the mechanisms of disease progression, there is still a lack of precise knowledge about immunopathogenesis, which reduces the effectiveness of treatment. Only a thorough understanding of molecular mechanisms will allow the final progress towards selective functionally targeted drugs. The article focuses on the immunological basis of the disease. In the most comprehensive part, it is a review of the latest global research on the inflammatory response. In the part devoted to pharmacotherapy, in addition to the reminder of classic medicines, it analyzes the latest global achievements in the field of biological and biosimilar medicines, including those awaiting registration.
Keyword: rheumatoid arthritis NSAIDs GCs csDMARDs tsDMARDs boDMARDs bsDMARDs.
© Farm Pol, 2019, 75(5): 271–276